Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.virusres.2020.198137 http://scihub22266oqcxt.onion/10.1016/j.virusres.2020.198137 32827627!7437510!32827627     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Virus+Res 2020 ; 288 (ä): 198137 Nephropedia Template TP {{tp|p=32827627|t=2020. Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials |pdf=|usr=}}{{32827627}} gab.com Text Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials JO: Virus Res http://www.kidney.de/pget.php?&tw=1&pmid=32827627 #FOAvip Several randomized controlled trials (RCTs) were conducted to investigate the effect of remdesivir for patients with COVID-19, but their results were conflicting. Thus, we conducted a network meta-analysis comparing the rate of clinical improvement among patients with COVID-19 who received 5-day course of remdesivir versus 10-day course of remdesivir versus standard care. Our network meta-analysis of 4 randomized controlled trials demonstrated that the rate of clinical improvement was significantly higher in the 5-day remdesivir group and 10-day remdesivir group compared to standard care group (OR [95% confidence interval [CI]] =1.89 [1.40-2.56], P <0.001, OR [95% CI] =1.38 [1.15-1.66], P <0.001, respectively). In addition, the rate of clinical improvement was significantly higher in the 5-day remdesivir group compared to the 10-day remdesivir group (OR [95% confidence interval [CI]] =1.37 [1.01-1.85], P =0.041). Our analysis demonstrated that the use of remdesivir for patients with COVID-19 was associated with the significantly higher clinical improvement rate compared with standard care alone. Twit Text FOAVip Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials ????Virus Res http://www.kidney.de/pget.php?&tw=1&pmid=32827627 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32827627 #FOAvip English Wikipedia <ref>{{Cite pmid|32827627}}</ref> Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials #MMPMID32827627 Yokoyama Y; Briasoulis A; Takagi H; Kuno T Virus Res 2020[Oct]; 288 (ä): 198137 PMID32827627show ga Several randomized controlled trials (RCTs) were conducted to investigate the effect of remdesivir for patients with COVID-19, but their results were conflicting. Thus, we conducted a network meta-analysis comparing the rate of clinical improvement among patients with COVID-19 who received 5-day course of remdesivir versus 10-day course of remdesivir versus standard care. Our network meta-analysis of 4 randomized controlled trials demonstrated that the rate of clinical improvement was significantly higher in the 5-day remdesivir group and 10-day remdesivir group compared to standard care group (OR [95% confidence interval [CI]] =1.89 [1.40-2.56], P <0.001, OR [95% CI] =1.38 [1.15-1.66], P <0.001, respectively). In addition, the rate of clinical improvement was significantly higher in the 5-day remdesivir group compared to the 10-day remdesivir group (OR [95% confidence interval [CI]] =1.37 [1.01-1.85], P =0.041). Our analysis demonstrated that the use of remdesivir for patients with COVID-19 was associated with the significantly higher clinical improvement rate compared with standard care alone. |Adenosine Monophosphate/*analogs & derivatives/therapeutic use[MESH] |Alanine/*analogs & derivatives/therapeutic use[MESH] |Antimetabolites/*therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/*drug effects/growth & development/metabolism[MESH] |COVID-19[MESH] |Coronavirus Infections/diagnosis/*drug therapy/mortality/virology[MESH] |Disease Progression[MESH] |Drug Administration Schedule[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/*drug therapy/mortality/virology[MESH] |Randomized Controlled Trials as Topic[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Survival Analysis[MESH]Effect of remdesivir on patients with COVID-19: A network meta-analysi(epmc).pdf DeepDyve Pubget Overpricing